"New Insights at ACG Meeting: TissueCypher® Enhances Barrett's Esophagus Care"

Castle Biosciences TissueCypher® Barretts Esophagus test provides critical risk insights that can reshape clinical management and potentially reduce unnecessary procedures, enhancing care for patients at risk of esophageal cancer.

• The new data presented at the American College of Gastroenterology meeting highlights how the TissueCypher® Barretts Esophagus test offers insights beyond traditional pathology, aiding early intervention.
• Patients with Barretts esophagus can benefit from the tests ability to identify those with dysplasia, potentially preventing progression to esophageal cancer and unnecessary endoscopy procedures.
• Castle Biosciences, based in Friendswood, Texas, emphasizes that their innovative approach supports doctors of medicine in making informed decisions about patient care in Boynton Beach, Florida, and beyond.